Organization
Shanghai Cancer Center, Shanghai, China
6 abstracts
Abstract
Laparoscopic-assisted vs open surgery for low rectal cancer: 5-year outcomes of the LASRE randomized clinical trial.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China, Zhangzhou Affiliated Hospital, Fujian Medical University, Zhangzhou, China, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China,
Abstract
Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer.Org: Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China, Shanghai Medical College, Fudan University,
Abstract
The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.Org: Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China,
Abstract
Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.Org: Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor–positive, HER2-negative breast cancer: FINEST study.Org: Fudan University Shanghai Cancer Center, Shanghai Cancer Center, Shanghai, China, Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shangai, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd.,